DIA Biosimilars 2013

Europe

Sweden to invest $320 million in life sciences

Wednesday, September 12, 2012 10:41 AM

A delegation of four ministers from the Swedish government, led by the Prime Minister Fredrik Reinfeldt, confirmed the country's largest ever investment in life sciences as a key element of the ruling coalition's autumn budget and research and innovation bill.

More... »

Cenduit: Now with Patient Reminders

F2G completes $30M financing round for anti-fungal compounds

Thursday, September 6, 2012 07:48 AM

F2G, an antifungal drug discovery and development company based in Manchester, U.K., has completed a $30 million equity financing round, which will be used to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies.

More... »

CRF Health – eCOA Forum

CLC bio acquires Molegro

Wednesday, September 5, 2012 10:55 AM

CLC bio, a provider of bioinformatics solutions, has acquired Molegro, a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor and determination of molecule similarity.

More... »

Merck, employee representatives agree on efficiency plan for Germany

Wednesday, September 5, 2012 10:47 AM

Merck, a global healthcare company based in Darmstadt, Germany, has signed an agreement with employee representatives on an efficiency plan for the company's Germany operations.

More... »

Icon forms partnership with University College Dublin

Wednesday, September 5, 2012 10:13 AM

Icon,a global provider of outsourced development services, has entered into a strategic partnership with University College Dublin (UCD), Ireland’s largest third-level institution.

More... »

FDA approves new treatment for severe neutropenia in cancer patients

Tuesday, September 4, 2012 08:30 AM

The FDA has approved Sicor Biotech’s tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

More... »

U.K. general public has fundamental misunderstanding of cost and value of medicines

Monday, September 3, 2012 08:00 AM

A new survey commissioned by the ABPI, has revealed that the British public misunderstands the cost and value of medicines in the U.K.

More... »

EMD Millipore to acquire Biochrom

Thursday, August 23, 2012 09:54 AM

EMD Millipore, the life science division of Merck of Darmstadt, Germany, has decided to acquire Biochrom, a cell culture media specialist of Berlin, Germany. The closing price was not disclosed.

More... »

Shire joins ABPI

Tuesday, August 21, 2012 09:56 AM

Specialty biopharmaceutical company Shire has joined the Association of the British Pharmaceutical Industry (ABPI) as a full member.

More... »

Astellas Pharma Europe appoints Wood as senior director, market access

Monday, August 20, 2012 03:21 PM

Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma, has appointed Dr, Susan Wood as senior director, market access.

More... »

`
CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs